4 Healthcare Stock Stories Prescribed for Investors

Boston Scientific Corporation (NYSE:BSX): Closing price $9.12

The initial patient has been enrolled in a clinical investigation studying the use of the company’s WallFlex Biliary RX Stent, which is a self-expanding metal stent, as a bridge to surgery versus the absence of drainage prior to surgery. It is anticipated that this multi-center, prospective, randomized evaluation should enroll 294 patients at leading hospitals in Australia, Belgium, Canada, France, Hong Kong, India, Italy, and Japan. The first patient was enrolled by Professor Jacques Deviere of Erasme Hospital in Brussels.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BSX

Sanofi-Aventis (NYSE:SNY): Closing price $

On Wednesday, Sanofi and Regeneron Pharmaceuticals (NASDAQ:REGN) reported that the COMPARE and ASCERTAIN trials of sarilumab — marking the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection biweekly — have enrolled their first patients. The broad SARIL-RA clinical development program is concentrated upon adult populations suffering from moderate-to-severe rheumatoid arthritis, who are inadequate responders to either methotrexate or tumor necrosis factor alpha (TNF-alpha) inhibitor therapy.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SNY

Mylan (NASDAQ: MYL): Closing price $

Mylan said that its subsidiary Mylan Pharmaceuticals has received a final okay from the FDA for its Abbreviated New Drug Application for Zolmitriptan Tablets, 2.5 mg and 5 mg. This product constitutes the generic version of IPR Pharmaceuticals’ Zomig Tablets, and is indicated for the acute treatment of migraine with or without aura in adults. Zolmitriptan Tablets are to be used only where a clear diagnosis of migraine has been established. The product is not indicated to prevent of migraine attacks or cluster headaches.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MYL

Bristol-Myers Squibb Company (NYSE: BMY): Closing price $

Abstracts for the American Society of Clinical Oncology annual meeting should be released Wednesday at 6 p.m., prior to the meeting which begins on May 31.  Analyst Seamus Fernandez at Leerink Swann commented that “It was announced on April 29 that BMY’s abstract on IO combination therapy with nivolumab & Yervoy (ipilimumab) in melanoma was selected for the annual meeting “press cast,” which occurs at noon on May 15. As we approach the annual meeting of the American Society of Clinical Oncology (Friday, May 31, to Tuesday, June 4, 2013), the enthusiasm of BMY’s management team for immuno-oncology’s long-term prospects continues unabated.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BMY

Don’t Miss: How Will Marijuana Impact Colorado’s Pocketbook?

More from The Cheat Sheet